Written by Scott Matusow and Danny Cohen
There's been a lot of hype on Arbutus (ABUS) as of late. The company recently successfully beat back a challenge to their general Intellectual Property ((IP)) that Moderna (MRNA) claimed was invalid - Moderna lost.
However, we think the real story with Arbutus has to do with their 2 upcoming key milestones. To begin with, the more relevant to us is the upcoming multiple ascending dose study of AB-729 in Hepatitis B infection. Notably, AB-729 demonstrated promising early results in the single ascending dose portion of